Abstract Library

#3183 Clinical stratification of pancreatic neuroendocrine tumors by systematically integrating multimodal and clinical data

Introduction: Non-functional pancreatic neuroendocrine tumors (PanNETs) are heterogeneous with at least two transcriptome subtypes with differential biology, immune mechanisms and prognosis. However, it is challenging to understand how multimodal data interact with clinical variables and contribute to the disease heterogeneity and phenotypes.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Lawlor R, Mafficini A, Luchini C, Nyamundanda G,

Keywords: pancreatic neuroendocrine tumor, multimodal data integration, multiomics, clinical data integration, machine learning, artificial intelligence, subtypes, pancreatic cancer, phenotypes, PhenMap, mutations, gene expression, microRNA,

#2963 Intrinsic Gene Programs in Metastasis-like Primary Subtype Is Associated with Early Metastatic Evolution in Pancreatic Neuroendocrine Tumours

Introduction: Three molecular subtypes of pancreatic neuroendocrine tumours (PanNETs) have been described: insulinoma-like, intermediate and metastasis-like primary (MLP). The Latter is a non-functional tumours with highly metastatic potential. A mouse model of PanNET showed that MLP subtype has two different pathways of progression including stem/progenitor and epithelial-to-mesenchymal transition. However, the evolution of metastasis in patients requires further studies.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Lawlor R, Nyamundanda G, Ragulan C, Scarpa A,

Keywords: Pancreatic neuroendocrine tumors, metastasis, metastatic evolution, early metastasis, recurrence, prognosis, Patient tumours, cause and effect relationship, computational modeling, molecular subtypes, stages, metastatic potential,

#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations

Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Young K, Nyamundanda G, Ragulan C, Lawlor R,

Keywords: molecular subtypes, biomarker assay, clinical assay, patient prognosis, subtype-specific mutations, NanoString Technologies, low-cost assay, pancreatic neuroendocrine tumors, grades, PanNETassigner subtype, patient stratification, pnet,